Ketoprofen topical - Achelios Therapeutics

Drug Profile

Ketoprofen topical - Achelios Therapeutics

Alternative Names: ELS M11; Ketoprofen 2% gel – Achelios Therapeutics; Ketoprofen 5% gel – Achelios Therapeutics; Ketoprofen liquid spray – Achelios Therapeutics; Topofen™

Latest Information Update: 29 Dec 2015

Price : $50

At a glance

  • Originator Achelios Therapeutics
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Migraine
  • Phase I Osteoarthritis
  • Preclinical Sprains

Most Recent Events

  • 21 Dec 2015 Efficacy data from a phase Ib/IIa trial in Migraine released by Achelios Therapeutics
  • 17 Jun 2014 ELS M11 is available for licensing as of 17 Jun 2014.
  • 01 Mar 2014 Phase-I clinical trials in Migraine in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top